KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Current Investments (2023 - 2025)

Biocryst Pharmaceuticals' Cash & Current Investments history spans 9 years, with the latest figure at $274.7 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 26.99% year-over-year to $274.7 million; the TTM value through Dec 2025 reached $274.7 million, up 26.99%, while the annual FY2025 figure was $274.7 million, 26.99% up from the prior year.
  • Cash & Current Investments reached $274.7 million in Q4 2025 per BCRX's latest filing, up from $129.4 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $410.7 million in Q2 2023 to a low of $129.4 million in Q3 2025.
  • Average Cash & Current Investments over 3 years is $258.0 million, with a median of $249.3 million recorded in 2023.
  • The largest YoY upside for Cash & Current Investments was 26.99% in 2025 against a maximum downside of 60.8% in 2025.
  • A 3-year view of Cash & Current Investments shows it stood at $280.1 million in 2023, then decreased by 22.77% to $216.3 million in 2024, then rose by 26.99% to $274.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Cash & Current Investments are $274.7 million (Q4 2025), $129.4 million (Q3 2025), and $172.5 million (Q2 2025).